Catalyst Pharma Confirms NASDAQ Listing in 8-K Filing

Ticker: CPRX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1369568

Catalyst Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCatalyst Pharmaceuticals, Inc. (CPRX)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, exchange-listing, corporate-governance

TL;DR

**Catalyst Pharma just filed an 8-K confirming its stock is still listed on NASDAQ.**

AI Summary

Catalyst Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose that its common stock, with a par value of $0.001 per share, is registered on the NASDAQ Capital Market under Section 12(b) of the Securities Exchange Act of 1934. This filing primarily serves to update administrative information and confirm its listing status. For investors, this filing simply reaffirms the company's continued compliance and trading on a major exchange, which is a basic expectation for a publicly traded company.

Why It Matters

This filing confirms Catalyst Pharmaceuticals' continued listing on the NASDAQ Capital Market, ensuring its stock remains easily tradable for investors.

Risk Assessment

Risk Level: low — This filing is purely administrative and confirms standard listing information, posing no new risks.

Analyst Insight

This filing is administrative and does not provide new information that would warrant an immediate investment action. Investors should continue to monitor operational and financial performance.

Key Numbers

  • $0.001 — Par Value per Share (The stated par value of Catalyst Pharmaceuticals' common stock.)

Key Players & Entities

  • CATALYST PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
  • NASDAQ Capital Market (company) — the exchange where the common stock is registered
  • $0.001 (dollar_amount) — par value per share of common stock
  • January 8, 2024 (date) — date of the earliest event reported and filing date

Forward-Looking Statements

  • Catalyst Pharmaceuticals will continue to trade on the NASDAQ Capital Market. (CATALYST PHARMACEUTICALS, INC.) — high confidence, target: Ongoing

FAQ

What is the purpose of this 8-K filing by Catalyst Pharmaceuticals, Inc.?

The purpose of this 8-K filing is to report the date of the earliest event, January 8, 2024, and to confirm that Catalyst Pharmaceuticals, Inc.'s common stock, with a par value of $0.001 per share, is registered pursuant to Section 12(b) of the Securities Exchange Act of 1934 on the NASDAQ Capital Market.

On which stock exchange is Catalyst Pharmaceuticals, Inc.'s common stock registered?

Catalyst Pharmaceuticals, Inc.'s common stock is registered on the NASDAQ Capital Market, as stated in the filing under 'Name of Exchange on Which Registered'.

What is the par value of Catalyst Pharmaceuticals, Inc.'s common stock?

The par value of Catalyst Pharmaceuticals, Inc.'s common stock is $0.001 per share, as indicated in the filing under 'Title of Each Class'.

What was the 'Date of Earliest Event Reported' in this 8-K filing?

The 'Date of Earliest Event Reported' in this 8-K filing was January 8, 2024.

What is the Commission File Number for Catalyst Pharmaceuticals, Inc.?

The Commission File Number for Catalyst Pharmaceuticals, Inc. is 001-33057, as listed in the filing.

Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-01-08 08:10:00

Key Financial Figures

  • $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR

Filing Documents

01

Item 7.01 Regulation FD Disclosure On January 8, 2024, the Company posted a corporate presentation to its website that representatives of the Company may use from time to time in presentations or discussions with investors, analysts, or other parties. The information in this Item 7.01, including Exhibit 99.1, is furnished pursuant to Exhibit 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the limitations of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company's submission of this Form 8-K shall not be deemed as an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Forward-Looking Statements

Forward-Looking Statements This Form 8-K, the presentation, and the slide deck contain forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in the Company's Annual Report on Form 10-K for the fiscal year 2022 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website, or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein or therein, which speak only as of this date.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Presentation, dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Richard J. Daly Richard J. Daly President and CEO Dated: January 8, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.